Enhancing T cell immunotherapies with synthetic signalling receptors

Cellular immunotherapies against cancer have made great progress in recent years using engineered T-cells with synthetic protein receptors called chimeric antigen receptors (CARs). Researchers from Sai Reddy’s lab and colleagues at the University Hospital Basel now present a technology platform to speed up the discovery of CAR variants with enhanced tumour killing properties and use the genetic construction plan for engineering next-generation CAR T cells.

17.11.2022 by Carolin Arndt Foppa

Number of comments

Enlarged view: graphical abstract Reddy-Sai Nature Communications — Schematic overview of speedingCARs: an integrated approach for the rapid engineering of CARs (see Fig. 6 of the original publication).

Find original publication in Nature Communications:

Castellanos-Rueda, R, RB Di Roberto, F Bieberich, FS Schlatter, D Palianina, OTP Nguyen, E Kapetanovic, H Läubli, A Hierlemann, N Khanna and ST Reddy (2022) external pageSpeedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing. Nat Commun 13, 6555. https://doi.org/10.1038/s41467-022-34141-8

Learn about the Systems and Synthetic Immunology Lab led by Sai Reddy.